Friedreich Ataxia - Pipeline Review, H1 2018

Publisher Name :
Date: 06-Mar-2018
No. of pages: 83
Inquire Before Buying

Friedreich Ataxia - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2018, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 14 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Friedreich Ataxia - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Friedreich Ataxia - Overview
Friedreich Ataxia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Friedreich Ataxia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Friedreich Ataxia - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Bio Blast Pharma Ltd
BioElectron Technology Corp
BioMarin Pharmaceutical Inc
Biovista Inc
Catabasis Pharmaceuticals Inc
Ixchel Pharma LLC
Pfizer Inc
ProQR Therapeutics NV
Reata Pharmaceuticals Inc
STATegics Inc
Takeda Pharmaceutical Co Ltd
Voyager Therapeutics Inc
Friedreich Ataxia - Drug Profiles
(sodium phenylbutyrate + tauroursodeoxycholic acid) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADVM-063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGIL-FA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BB-FA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMN-290 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVA-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVA-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTI-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextro epicatechin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JOT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-604 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-3250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STSE-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vatiquinone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYFXN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Friedreich Ataxia - Dormant Projects
Friedreich Ataxia - Discontinued Products
Friedreich Ataxia - Product Development Milestones
Featured News & Press Releases
Oct 31, 2017: Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia
Aug 22, 2017: Jupiter Orphan Therapeutics Receives Orphan Drug Designation for its Trans-Resveratrol Product JOTROL for Treatment of Friedreich's Ataxia
Aug 03, 2017: Chondrial Announces FDA Orphan Drug Designation for CTI-1601, a Novel Investigational Technology for the Treatment of Friedreich's Ataxia
Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day
Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia
Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia
Aug 05, 2015: Key Patent Granted For AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's Ataxia
Jun 18, 2015: BioBlast Pharma to Present Preclinical Proofs of Concept in Friedreich's Ataxia at Two Leading Scientific Meetings in June
Mar 26, 2015: BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia
Mar 24, 2015: Catabasis Pharmaceuticals to Present at International Ataxia Research Conference
Dec 17, 2014: BioBlast Receives Notice of Patent Issuance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia
Mar 17, 2014: FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
Feb 04, 2014: FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia
Nov 04, 2013: Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations
Jan 07, 2013: Edison Pharma Initiates Phase IIb Clinical Trial Of EPI-743 In Friedreich Ataxia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Friedreich Ataxia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H1 2018
Friedreich Ataxia - Pipeline by Bio Blast Pharma Ltd, H1 2018
Friedreich Ataxia - Pipeline by BioElectron Technology Corp, H1 2018
Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H1 2018
Friedreich Ataxia - Pipeline by Biovista Inc, H1 2018
Friedreich Ataxia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H1 2018
Friedreich Ataxia - Pipeline by Pfizer Inc, H1 2018
Friedreich Ataxia - Pipeline by ProQR Therapeutics NV, H1 2018
Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H1 2018
Friedreich Ataxia - Pipeline by STATegics Inc, H1 2018
Friedreich Ataxia - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H1 2018
Friedreich Ataxia - Dormant Projects, H1 2018
Friedreich Ataxia - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Friedreich Ataxia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global and China Infantile Spasms Therapeutics Market Research by Company, Type & Application 2013-2025
    Published: 16-Aug-2019        Price: US 2000 Onwards        Pages: 75
    Summary An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending for......
  • Global (United States, European Union and China) Acute Ischemic Stroke Therapeutics Market Research Report 2019-2025
    Published: 16-Aug-2019        Price: US 3280 Onwards        Pages: 118
    AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternat......
  • Global and China Brachytherapy Afterloader Seeds Market Research by Company, Type & Application 2013-2025
    Published: 16-Aug-2019        Price: US 2000 Onwards        Pages: 80
    Summary Brachytherapy also known as internal radiotherapy, sealed source radiotherapy, curie therapy or endocurietherapy, is a form of radiotherapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, and skin cancer and can also be used to treat tumors in many other body sites.Brachytherapy Afterloaders, is kind of machine used in brachytherapy to delivere......
  • Global (United States, European Union and China) Varicose Vein Treatment Market Research Report 2019-2025
    Published: 15-Aug-2019        Price: US 3280 Onwards        Pages: 118
    Varicose Veins also referred to as varicosities are swollen, blue, twisted veins that appear on the skin. These are often seen near the legs. In 2019, the market size of Varicose Vein Treatment is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the......
  • Global Clostridium Difficile Treatment Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 13-Aug-2019        Price: US 3000 Onwards        Pages: 122
    Summary The report forecast global Clostridium Difficile Treatment market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2024. The report offers detailed coverage of Clostridium Difficile Treatment industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Clostridium Difficile Treatment by geography. The report spl......
  • Global Post-Traumatic Stress Disorder Therapeutics Industry Market Research Report
    Published: 13-Aug-2019        Price: US 2960 Onwards        Pages: 130
    The Post-Traumatic Stress Disorder Therapeutics market revenue was xx.xx Million USD in 2014, grew to xx.xx Million USD in 2018, and will reach xx.xx Million USD in 2024, with a CAGR of x.x% during 2019-2024. Based on the Post-Traumatic Stress Disorder Therapeutics industrial chain, this report mainly elaborates the definition, types, applications and major players of Post-Traumatic Stress Disorder Therapeutics market in details. Deep analysis about market status (2014-2019), enterprise competit......
  • Global (United States, European Union and China) Anti-inflammatory Therapeutics Market Research Report 2019-2025
    Published: 13-Aug-2019        Price: US 3280 Onwards        Pages: 117
    Anti-inflammatory therapeutics are primarily used to reduce inflammation. These drugs are types of analgesics that are used for reducing pain. The global anti-inflammatory therapeutics market will grow steadily at a CAGR of over 6% by 2021. This market research analysis identifies the increase in the prevalence of immune-mediated inflammatory disease (IMID) as one of the primary growth factors for this market. IMID includes a group of disabling conditions that share a common inflammatory ......
  • Global Hormone Replacement Therapy Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 12-Aug-2019        Price: US 3000 Onwards        Pages: 104
    Summary The report forecast global Hormone Replacement Therapy market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2024. The report offers detailed coverage of Hormone Replacement Therapy industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Hormone Replacement Therapy by geography. The report splits the mark......
  • Global Virus Like Particles Market Status (2015-2019) and Forecast (2020-2024) by Region, Product Type & End-Use
    Published: 12-Aug-2019        Price: US 3000 Onwards        Pages: 130
    Summary The report forecast global Virus Like Particles market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2024. The report offers detailed coverage of Virus Like Particles industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Virus Like Particles by geography. The report splits the market size, by volume an......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs